Integrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Disease, Including Eye Bulging, Double Vision and Quality of Life

DUBLIN--(BUSINESS WIRE)--Horizon announced that integrated data for teprotumumab for the treatment of active thyroid eye disease (TED) were presented at the ATA Annual Meeting

Full Story →